A drug already prescribed to shrink benign, enlarged prostates has been shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease, a large international trial has found. The four-year study found that dutasteride (Avodart) significantly reduced the chances that men would be diagnosed with the kinds of tumors that are most often treated excessively.